Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.38 |
| ▸ | USP10 | Q14694 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | USP13 | Q92995 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22714321 | 1.00 | LMNA (0.42) | LMNACLK4USP10PIK3C3USP13 | |
| SCHEMBL22714592 | 0.89 | LMNA (0.36) | LMNACLK4USP10PIK3C3USP13 | |
| SCHEMBL29563967 | 0.89 | LMNA (0.36) | LMNACLK4USP10PIK3C3USP13 | |
| SCHEMBL24673902 | 0.86 | LMNA (0.48) | LMNACLK4USP10PIK3C3USP13 | |
| SCHEMBL29564796 | 0.86 | LMNA (0.48) | LMNACLK4USP10PIK3C3USP13 | |
| SCHEMBL22714286 | 0.83 | LMNA (0.38) | LMNACLK4MEN1KMT2A | |
| SCHEMBL29564279 | 0.83 | LMNA (0.38) | LMNACLK4MEN1KMT2A | |
| SCHEMBL24674487 | 0.81 | LMNA (0.40) | LMNACLK4MEN1KMT2A | |
| SCHEMBL22714307 | 0.79 | EGFR (0.43) | LMNACLK4EGFR | |
| SCHEMBL29564287 | 0.79 | EGFR (0.43) | LMNACLK4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976609-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | claimed |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-04-21 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | LMNA 3597/4885CLK4 3985/4885USP10 4192/4885 |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX2 | LMNA 2712/4885CLK4 3486/4885USP10 4344/4885 |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | LMNA 3597/4885CLK4 3985/4885USP10 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.